PeerVoice Heart & Lung Audio PeerVoice

Visit https://www.peervoice.com/KHV860 to view the entire programme with slides. After completing “Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making”, participants will be able to: Identify best practices to optimize the recognition and diagnosis of patients with transthyretin amyloidosis (ATTR), including those with ATTRv-PN and those with mixed phenotype ATTR; Evaluate current and emerging treatment options for hereditary ATTR with polyneuropathy (ATTRv-PN), including key differences between therapies with regards to clinical trial design, patient populations studied, available outcomes, and administration considerations; and Apply a comprehensive, patient-centered approach to management of patients with ATTR, including those with ATTRv-PN and those with mixed phenotype ATTR.

Visit https://www.peervoice.com/DRF860 to view the entire programme with slides. After completing “Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia”, participants will be able to: Recognize health risks associated with idiopathic hypersomnia; Differentiate idiopathic hypersomnia from other conditions that cause excessive daytime sleepiness (EDS); Explain how to establish a confirmatory diagnosis of idiopathic hypersomnia; and Propose effective, individualized, evidence-based management strategies for patients with idiopathic hypersomnia.

Visit https://www.peervoice.com/RHA860 to view the entire programme with slides. After completing “Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy”, participants will be able to: Describe the pathophysiology of narcolepsy in the context of cardiovascular (CV) effects; Differentiate between narcolepsy medications regarding their impact on CV risk factors; Identify medications used for common comorbidities associated with narcolepsy that have the potential to increase CV risk; and Propose strategies to manage CV risk in patients with narcolepsy.

Visit https://www.peervoice.com/QHY860 to view the entire programme with slides. After completing “Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC”, participants will be able to: A key challenge is that physicians cannot simply order a “MET test”; different tests must be used to detect the different alterations;; Exon 14 skipping mutations, amplification, and fusion can be detected via DNA or RNA-based next-generation sequencing (NGS);; Amplification and fusion may also be detected by fluorescence in situ hybridization (FISH);; and Overexpression is detected via immunohistochemistry (IHC)..

Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

Visit https://www.peervoice.com/ZFW860 to view the entire programme with slides. After completing “Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care”, participants will be able to: Summarise key data which informs guideline-driven interventions for patients with chronic obstructive pulmonary disease (COPD); Identify treatable traits which can guide need for non-pharmacologic interventions and selection of pharmacotherapy, including triple therapy, for patients with COPD; and Use patient- and disease-specific considerations and treatable traits to guide comprehensive management strategies for patients with COPD.